What is the main purpose of this 8-K filing for Johnson & Johnson?

The main purpose of this 8-K filing is to formally announce and provide access to Johnson & Johnson's financial results for the second quarter ended July 2, 2023. It serves as a regulatory mechanism to disseminate this important financial information to investors and the public via an attached press release and supplementary financial data.

Where can I find the detailed Q2 2023 financial results for JNJ?

The detailed Q2 2023 financial results are primarily located in Exhibit 99.1 (the Press Release dated July 20, 2023) and Exhibit 99.2 (Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings) attached to this 8-K filing.

What specific financial information should I look for in the attached exhibits?

Investors should look for key financial metrics such as total sales, sales by segment (Pharmaceuticals, MedTech), earnings per share (EPS), net income, and any year-over-year comparisons or growth rates. The supplementary data will also provide more granular details on revenue and earnings.

Does this 8-K filing contain any new strategic announcements or business updates beyond the Q2 results?

Based on the provided filing details, this 8-K is specifically focused on reporting the Q2 2023 financial results. While press releases often contain management commentary that might touch upon ongoing strategies, the core purpose and content highlighted are the financial performance figures. For major strategic updates, investors should monitor other SEC filings and company communications.

JNJ 8-K: Earnings & Results

Summary

Johnson & Johnson (JNJ) filed an 8-K on July 20, 2023, primarily to announce its second-quarter 2023 financial results. The report includes details on sales and earnings for the quarter ended July 2, 2023, as presented in an attached press release (Exhibit 99.1). This filing is crucial for investors seeking to understand the company's recent performance and financial health. While the 8-K itself is brief and acts as a vehicle for the press release, the information contained within that release is critical. Investors should pay close attention to the reported sales figures, earnings per share, and any commentary on the performance of JNJ's key business segments, including Pharmaceuticals and MedTech. The supplementary sales data and condensed consolidated statement of earnings provide a more detailed financial picture for the quarter and year-to-date period.

Key Highlights

1JNJ filed an 8-K on July 20, 2023, to report its Q2 2023 financial results.
2The report references a press release (Exhibit 99.1) containing detailed sales and earnings information for the quarter ended July 2, 2023.
3Unaudited comparative supplementary sales data and condensed consolidated statements of earnings are provided as Exhibit 99.2.
4The filing's primary purpose is to formally disclose the company's Q2 financial performance to the public.
5Investors can refer to the attached exhibits for specific financial metrics and operational performance details.
6The event date for the information contained in the filing was July 19, 2023, with the filing occurring on July 19, 2023.

JOHNSON & JOHNSON 8-K Report, Financial Results (Jul 20, 2023)

Summary

Key Highlights

Frequently Asked Questions